ABSTRACT
clinically evaluable patients was 94.1% in the levofloxacin group and 92.3% in the azithromycin group. The respective posttherapy microbiologic eradication rates were 89.5% and 92.3%. Levofloxacin was as well tolerated as azithromycin, with an incidence of drug-related adverse events (AEs) for all body systems of 5.3% and 9.3%, respectively. One patient receiving levofloxacin had a serious drug-related AE, compared with 7 patients receiving azithromycin.
Conclusions: In this study in hospitalized patients with moderate to severe CAP, levofloxacin monotherapy was at least as effective as a combination regimen of azithromycin and ceftriaxone in providing coverage against the current causative pathogens in CAP. In addition, levofloxacin was as well tolerated as the combination of azithromycin and ceftriaxone.
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INTRODUCTION
Despite the availability of effective antimicrobial agents, community-acquired pneumonia (CAP) remains a potentially life-threatening infection of the lower respiratory tract. The overall mortality rate among patients hospitalized with CAP ranges from 5% to 25%, whereas the mortality rate in those with severe illness requiring treatment in the intensive care unit ranges from 20% to 50%.lJ Streptococcus pneumoniae is the most common etiologic agent in hospitalized patients with CAP, particularly those with severe disease. 3,4 Pneumococcal bacteremia is a major complication in hospitalized patients with CAP, with an attributable mortality rate ranging from 20% to 4 1% . 5 The mortality rate in patients with severe CAP who are bacteremic is -3 times that in patients with severe CAP who have negative blood cultures6
The significant risk of bacteremia in patients with moderate to severe CAP supports selection of an antibiotic regimen for initial in-hospital therapy that is active against the main causative pathogens while achieving high drug concentrations in plasma and lung tissue. Results of a retrospective investigation in patients with severe bacteremic pneumococcal pneumonia suggest that monotherapy may produce suboptimal outcomes in this population. 7 However, a retrospective review of 98 cases of CAP-associated pneumococcal bacteremia from prospective, randomized, controlled clinical trials demonstrated a clinical success rate of 96.9% and a microbiologic success rate of 95.9% with levofloxacin 500 mg/d. 8 In addition, the Infectious Diseases Society of America (IDSA) recommends use of doxycycline, macrolides, or fluoroquinolones for the empiric treatment of most outpatient cases of CAP and either a fluoroquinolone alone or a beta-lactatieta-lactamase inhibitor or extended-spectrum cephalosporin combined with a macrolide for most hospitalized patients with CAP in a general medical ward?
This study compares the efficacy and tolerability of 2 regimens -monotherapy with levofloxacin and combination therapy with azithromycin and ceftriaxonethat meet IDSA criteria for the treatment of CAP. Both are used for empiric treatment of moderate to severe CAP, although recently there has been increased concern about the association of macrolides with macrolide-resistant pneumococcal bacteremia.lO,ll
PATIENTS AND METHODS
Study Design
This was a Phase IV, multicenter, openlabel, randomized trial comparing the efficacy and tolerability of levofloxacin monotherapy and the combination of azithromycin and ceftriaxone in hospitalized patients with moderate to severe CAP.
Znclusion and Exclusion Criteria
Patients aged 218 years were eligible for the study if they had a diagnosis of moderate to severe pneumonia acquired in the community or in a nursing home. The diagnostic criteria included (1) characteristic clinical signs, including ~1 of the following-fever (oral temperature >38"C), hypothermia (oral temperature <35.5"C), leukocytosis (>lO,OOO white blood cells/mm3), or bands >lO%; (2) radiologic evidence of pneumonia (an acute infiltrate consistent with pneumonia on chest radiography); (3) collection of a mucopurulent sputum specimen for culture and Gram's staining within 24 hours before study drug administration; and (4) a Fine risk score12 of 71 to 130 (indicative of moderate to severe disease and associated need for hospitalization) at study inclusion. Patients who had received previous antimicrobial therapy for any infection were allowed to participate if the total duration of previous therapy was ~24 hours or the patient had received >72 hours of therapy but was classified as a treatment failure.
Women of childbearing potential were required to have had normal menstrual flow in the month before study entry, to have a negative result on serum pregnancy testing (human chorionic gonadotropin l3 subunit) immediately before study entry or a negative urine pregnancy test (sensitive to 50 mIU/mL) if serum pregnancy testing would delay treatment; and to have been using hormonal contraception for 2 1 month before study entry, to have an intrauterine device, or to consent to using a spermicide/barrier method of contraception. Whichever method of contraception was in use at the time of study entry was to be continued throughout the study. Women who had been postmenopausal for 81 year or had been rendered surgically menopausal were also eligible.
Patients were excluded from study participation if they had an infection caused by a pathogen known or suspected to be resistant to any of the study drugs before their admission to the study or if they had experienced an allergic reaction or serious adverse reaction to levofloxacin, azithromycin, ceftriaxone, or any other member of the quinolone, macrolide, or beta-lactam class of antimicrobial agents. Patients were also ineligible if they had been hospitalized within 2 weeks before study entry (or within 1 month before study entry if antimicrobial therapy had been administered during this time), or if their life expectancy was ~72 hours.
Other exclusion criteria included creatinine clearance <20 mL/min (when only serum creatinine data were available, the Cockcroft-Gault equation was used to calculate creatinine clearance); empyema or the presence of pleural fluid requiring an indwelling chest tube; pneumonia due to aspiration of gastric contents; HIV infection, with a CD4 cell count <200/cm3; presence of any seizure disorder or a psychiatric condition requiring chronic use of tranquilizers;
or presence of any disease or disorder that could interfere with evaluation of the study treatments. Patients who had received any experimental drug within 30 days before study entry were also excluded.
All patients, or their legally authorized representatives, provided written informed consent.
Study Treatments
Randomization was conducted according to a computer-generated schedule prepared by Ortho-McNeil before initiation of the study. Patients were randomized in a 1: 1 ratio to 1 of 2 treatment groups: levofloxacin 500 mg PO or IV q24h, or azithromycin 500 mg IV q24h for 22 days plus ceftriaxone 1 g IV q24h for 2 days, followed by an optional transition to azithromycin 500 mg PO q24h at the investigator's discretion. Ceftriaxone was included in the initial azithromycin regimen to ensure coverage against pneumococcal bacteremia. The first dose of study drug was administered as soon as admission procedures were completed and could be given in the emergency department. Thereafter, all doses were administered in the morning. Oral levofloxacin therapy could be started at the time of study entry or as soon as oral medication could be tolerated. The duration of therapy was to be a total of 10 days in both treatment groups.
Levofloxacin could be administered without regard to meals, whereas oral azithromycin was taken 21 hour before or >2 hours after a meal. In the levofloxacin group, patients with a calculated creatinine clearance of 20 to 49 mL/min received an initial loading dose of levofloxacin 500 mg, followed by 250 mg q24h. Patients with hepatic or renal impairment were administered azithromycin and ceftriaxone with caution, as specified in the respective package inserts.
The use of systemic corticosteroids was contraindicated during the study, unless such therapy was already being received for an unrelated medical condition. Patients requiring antacid therapy were strongly advised to use compounds containing calcium carbonate rather than magnesium-aluminum hydroxide or sucralfate. If either of the latter was used, it was to be taken >2 hours after study drug administration.
Theophylline levels were closely monitored as clinically appropriate in both treatment groups, with dose adjustment as necessary. Because concurrent use of macrolides or some quinolones and warfarin or its derivatives has been associated with increased anticoagulant effects in clinical practice,13 the prothrombin time was closely monitored as clinically indicated in patients receiving warfarin or its derivatives. Given reports of drug interactions between macrolides and digoxin, ergotamine/dihydroergotamine, triazolam, carbamazepine, terfenadine, cyclosporine, hexobarbital, and phenytoin,14 patients receiving any of these drugs in combination with azithromytin were monitored closely as clinically indicated.
Study Evaluations
Patients were evaluated at the initial (admission) visit, at which time a medical history was obtained and a physical examination was performed. The severity of pneumonia was assessed in terms of the Fine risk score,'* and posteroanterior and lateral chest radiographs were obtained. All patients were required to have a mucopurulent sputum specimen, which was sent for Gram's staining and culture. A urine specimen was obtained for pregnancy testing, if applicable. Blood sam-ples were obtained for culture, serum pregnancy testing, complete blood count with differential, and measurement of arterial pH, blood urea nitrogen, sodium, glucose, and arterial partial pressure of oxygen. Any concomitant therapies were recorded. Treatment with study drug was then initiated.
Patients' clinical status was evaluated -72 hours after the start of treatment (days 3-5). Those whose condition had not stabilized or whose clinical signs/symptoms had worsened after 72 hours were withdrawn from the study and were considered treatment failures. These patients were switched to an appropriate alternative therapy. Those whose condition had stabilized but was not yet improved could continue in the study at the investigator's discretion. Patients whose admission organism was determined to be resistant to study drug could also remain in the study at the investigator's discretion, provided they were clinically stable or improving.
General, nondirected questioning was used to elicit adverse events (AEs) occurring during treatment. Blinding to treatment assignment was not possible because of the investigator's freedom to change the route of administration or discontinue ceftriaxone .
Between days 2 and 7 after the completion of therapy (or at early withdrawal), a physical examination was performed, including recording of vital signs. Clinical signs and symptoms were evaluated, and the patient's clinical response was assessed. Posteroanterior and lateral chest radiographs were obtained, as was a sputum sample for Gram's staining and culture, if available. If the admission culture had been positive or the patient was considered a clinical failure, a blood sample was drawn for routine culture. Patients were questioned about any AEs that had occurred during the study.
Ef$cacy and Safety Assessments
The primary efficacy variable was the clinical response at the posttherapy (or early-withdrawal) assessment in clinically evaluable patients (see Statistical Analysis section for definitions of study populations). Secondary efficacy variables included the posttherapy microbiologic response by infection; the posttherapy microbiologic response for each pathogen isolated from an admission sputum culture; and the posttherapy microbiologic response for blood pathogens isolated at admission.
Clinical Ejkacy
Clinical efficacy was assessed by comparing the signs, symptoms, and radiologic findings from the posttherapy (or earlywithdrawal) evaluation with those from the admission evaluation. The following definitions were used to categorize the clinical response: clinical cure-resolution of pretreatment clinical signs and symptoms (radiographic resolution not required) and no need for additional antimicrobial therapy; improved-significant improvement in clinical findings, but clinical evidence of resolution incomplete during therapy or at follow-up evaluation in a patient not requiring additional antimicrobial therapy; failure-incomplete response or no apparent response to therapy, and need for additional antimicrobial therapy; and unevaluable-clinical evaluation of cure, improvement, or failure not possible because of inadequate follow-up data, use of concomitant antimicrobial therapy, or protocol violation. identified any organisms that had been susceptible to study treatment at admission but subsequently acquired resistance.
Microbiologic Eficacy
At the posttherapy evaluation, each patient's infection was assigned to 1 of the following categories of microbiologic response based on the microbiologic response of all pathogens isolated in that patient at admission: eradicated/presumed eradicated-all pathogens isolated at admission were eradicated or presumed to have been eradicated; mixed-2 1 pathogen isolated at admission was eradicated or presumed to have been eradicated, while others persisted or were presumed to have persisted; persisted/presumed persistedall pathogens isolated at admission persisted or were presumed to have persisted; and unable to evaluate-a judgment could not be made.
Bacteremia was defined as 1 blood culture result positive for a pathogen at admission. In patients for whom no blood culture was available at the posttherapy evaluation, the microbiologic response was classified as unknown if the clinical response was cured or improved and as presumedpersisted if the clinical response was failure. Superinfection was defined as the emergence or worsening of clinical signs and symptoms requiring additional antimicrobial therapy when a pathogen not isolated at admission was isolated from any site through the posttherapy evaluation.
Safety
Tolerability was assessed based on findings of the physical examinations and laboratory tests performed during the study and AEs reported by patients. Safety parameters were assessed separately for oral and parenteral therapy. Treatmentemergent AEs were defined as new-onset AEs or existing AEs whose severity or frequency was exacerbated after administration of study drug, based on the investigator 's judgment.
Analysis Plan
Five populations were identified for the purposes of analysis. The intent-to-treat population included all randomized patients. The modified intent-to-treat population included those patients who had a confirmed diagnosis of moderate to severe CAP and received sl dose of study drug. The clinically evaluable population included patients who had clinical signs/ symptoms at admission and a chest radiograph consistent with acute pneumonia; had a clinical response other than unable to evaluate; had received consecutive doses of protocol-specified drug on days 1 through 3 at minimum and ~7 doses during the first 10 days (patients who discontinued study treatment as a result of clinical failure after 72 hours of consecutive therapy were considered evaluable); had received no concomitant or posttherapy treatment with another effective systemic antibiotic; and had a valid posttherapy evaluation.
The microbiologically evaluable population included patients who were evaluable for clinical efficacy; had a specimen for culture obtained within 24 hours before starting study treatment; had an admission pathogen recognized as a potential cause of CAP; and had a valid posttherapy evaluation, including a specimen for culture, if available. The safety population included patients who took ~1 dose of study medication.
The primary efficacy variable was the posttherapy clinical response (cured, improved, failed, or unable to evaluate) in clinically evaluable patients. Clinical success was derived by combining the clinical responses cured and improved. Clinical success rates and by-patient microbiologic eradication rates were analyzed by treatment group for each population.
To evaluate whether levofloxacin was at least as effective as azithromycin, 2-sided 95% CIs (normal approximation to the binomial with a continuity correction)
were computed around the treatment differences (azithromycin -levofloxacin) in posttherapy response rates.15 Statistical equivalence (ie, levofloxacin at least as effective as azithromycin) was considered to be demonstrated if the 95% CI crossed zero and the upper limit was s15%. 16 Posttherapy microbiologic eradication rates were summarized for microbiologitally evaluable patients in each treatment group by pathogen category (grampositive vs gram-negative aerobes); pathogen and infection overall; and pathogen within each culture category (respiratory, blood, most prevalent pathogens). Twosided 95% CIs were computed around the treatment differences (azithromycin -levofloxacin) in posttherapy microbiologic response rates. In microbiologically evaluable patients, a cross-tabulation of by-patient microbiologic response versus clinical response was performed. Pathogens were classified by those isolated from respiratory cultures and those isolated from blood cultures. In clinically evaluable patients, posttherapy clinical response rates by pathogen within each culture category were summarized for the most prevalent pathogens (those isolated at admission from ~5 patients in each treatment group).
Approximately 198 patients were to be randomized to treatment to provide 148 clinically evaluable patients, with a minimum of 74 patients in each treatment group. This would provide 80% power to test the null hypothesis, assuming an 88% clinical success rate in each of the treatment groups, at a significance level of 0.025.
RESULTS
Between December 15,1997, and June 7, 1999, 236 patients were randomized to treatment and received 1 of the 2 study regimens (Table I) . These patients composed the intent-to-treat population. The levofloxacin group received IV treatment *Comparator regimen consisted of azithromycin 500 mg IV q24h for r2 days plus ceftriaxone 1 g IV q24h for 2 days, followed by an optional switch to azithromycin 500 mg PO q24h at the investigator's discretion. +Percentages are based on number of patients with completion/withdrawal information. 'Patients in ITT population with a confirmed diagnosis of moderate to severe community-acquired pneumonia who took rl dose of study drug.
for a mean of 3.67 days, and the azithromycin group received IV treatment for a mean of 3.83 days (plus a mean 2.36 days of IV ceftriaxone).
Five patients in the levofloxacin group and 7 in the azithromycin group were lost to follow-up (eg, were transferred to another facility). Completion/withdrawal data were therefore available for 110 patients in the levofloxacin group and 114 in the azithromytin group. Twenty-three (20.9%) patients in the levofloxacin group withdrew prematurely: 5 (4.5%) due to AEs, 4 (3.6%) for clinical failure, 3 (2.7%) due to a negative radiograph, and 11 (10.0%) for personal or other reasons or because no study drug was taken. Thirty-five (30.7%) patients in the azithromycin group withdrew prematurely: 5 (4.4%) due to AEs, 6 (5.3%) for clinical failure, 4 (3.5%) due to a negative radiograph, and 20 (17.5%) for personal or other reasons or because no study drug was taken. A total of 211 patients were included in the modified intent-to-treat population, 163 of whom were clinically evaluable and 7 1 of whom were microbiologically evaluable. Baseline demographic and disease characteristics were similar in clinically evaluable patients in the 2 treatment groups (Table II) . The mean duration of pneumonia at baseline was 7.3 days, and the mean Fine risk score was 93.4. Somewhat less than one third (47/163) of patients were current smokers, with a history of 68.9 pack years (data not shown). Table III lists the clinical response rates at the posttherapy (or early-withdrawal) evaluation.
In clinically evaluable patients, the clinical success rate was 94.1% in the levofloxacin group and 92.3% in the azithromycin group (95% CI, -10.20 to 6.58). The clinical success rates in the modified intent-to-treat population were a respective 89.6% and 85.7% (95% CI, -13.24 to 5.43). In microbiologically *Patients with clinical signs/symptoms and a chest radiograph consistent with acute pneumonia at admission who had a clinical response other than unable fo evalua?e, had received consecutive doses of study drug on days 1 through 3 and k7 doses in the first 10 days and no concomitant or posttherapy treatment with another systemic antibiotic, and had a valid posttherapy evaluation. tcomparator regimen consisted of azithromycin 500 mg IV q24h for 22 days plus ceftriaxone 1 g IV q24h for 2 days, followed by an optional switch to azithromycin 500 mg PO q24h at the investigator's discretion. "A score of 71 to 130 is indicative of moderate to severe disease and associated need for hospitalization. +Comparator regimen consisted of azithromycin 500 mg IV q24h for r2 days plus ceftriaxone 1 g IV q24h for 2 days, followed by an optional switch to azithromycin 500 mg PO q24h at the investigator's discretion. *Two-sided 95% CI around the difference (comparator regimen -levofloxacin) in clinical success rates. "Five patients in the levofloxacin group and 10 patients in the comparator group were considered clinical successes based solely on the evaluation conducted during therapy. "Four patients in the levofloxacin group and 2 patients in the comparator group were considered clinical successes based solely on the evaluation conducted during therapy.
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evaluable patients, the clinical success rates were 91.7% and 94.3%, respectively (95% CI, -10.67 to 15.91). Twelve patients in the levofloxacin group received only oral levofloxacin therapy. The clinical success rate in these patients was 100%.
Clinical and microbiologic response rates were comparable within each treatment group (Table IV) . All 33 microbiologically evaluable patients in the levofloxacin group who had a posttherapy microbiologic response of eradicated had a clinical response of cure or improved. The 3 patients with a microbiologic response of persisted were classified as clinical failures. Of 3.5 patients in the azithromycin group who were microbiologically evaluable and had a posttherapy microbiologic response of eradicated, 33 (94.3%) had a clinical response of cure or improved. The remaining 2 (5.7%) patients were considered clinical failures.
S pneumoniae was isolated from sputum cultures obtained from 29 patients, 14 in the levofloxacin group and 15 in the azithromycin group. Haemophilus injluenzae was isolated from sputum cultures obtained from 22 patients, 9 in the levofloxacin group and 13 in the azithromycin group. The eradication rate for S pneumoniae in sputum cultures was 100% in both the levofloxacin and azithromycin groups (95% CI, -3.57 to 3.57); the eradication rate for H injkenzae was also 100% in both groups (95% CI, -5.56 to 5.56). S pneumoniae was also isolated from blood cultures obtained from 5 patients in the clinically evaluable population, 3 in the levofloxacin group and 2 in the azithromycin group. The eradication rate for Spneumoniae in blood cultures was 100% in both the levofloxacin and azithromycin groups. All other pathogens isolated from respiratory or blood cultures occurred in <5 patients in either treatment group. *Microbiologic eradication rates are per patient (ie, they reflect eradication of all pathogens isolated at admission from a particular patient). +Persisted rates include the infection categories persisted, mixed, and unable to evaluate. *Comparator regimen consisted of azithromycin 500 mg IV q24h for 22 days plus ceftriaxone 1 g IV q24h for 2 days, followed by an optional switch to azithromycin 500 mg PO q24h at the investigator's discretion. Table V presents the susceptibilities to  tin are shown in Table VI . Of 103 isolates the study drugs of the 122 bacterial isothat were susceptible to levofloxacin, 95 lates cultured at admission. The susceptiwere also susceptible to azithromycin, 1 bilities of 18 isolates were unknown. Of was intermediately susceptible, and 7 were 104 admission isolates for which susceptiresistant. The 1 isolate that was intermedibilities were determined, 103 were suscepately susceptible to levofloxacin was resistible to levofloxacin, 95 to azithromycin, tant to azithromycin. Table VII shows and 100 to ceftriaxone. One isolate was inthe cross-susceptibilities of admission termediately susceptible to levofloxacin, 1 pathogens to levofloxacin and ceftriaxone. was intermediately susceptible to azithroOf 103 isolates that were susceptible to mycin, and 3 were intermediately susceplevofloxacin, 99 were also susceptible to tible to ceftriaxone. None of the 104 isoceftriaxone, 3 were intermediately susceplates were resistant to levofloxacin, tible, and 1 was resistant. The 1 isolate that whereas 8 were resistant to azithromycin was intermediately susceptible to levoand 1 was resistant to ceftriaxone.
floxacin was susceptible to ceftriaxone. The cross-susceptibilities of admission pathogens to levofloxacin and azithromy-
The clinical characteristics of the 5 patients classified as treatment failures are Fg/mL). Because H injluenzae is considered susceptible to azithromycin if its MIC is 54.0 p,g/mL and E coli is considered susceptible if its MIC is 52 pg/mL, the former was susceptible to azithromycin. None of the cases of pneumococcal bacteremia involved a resistant organism.
Safety Assessment
The safety population consisted of 113 patients in the levofloxacin group and 118 in the azithromycin group. As seen in CHF = congestive heart failure; L = levofloxacin; A = azithromycin; C = ceftriaxone; NA = not available. *Number of days before discontinuation of study drug. tMicrobiologically evaluable patient in whom causative pathogens were not eradicated. SPatient died of multiorgan failure after 6 days. %Jomparator regimen consisted of azithromycin 500 mg IV q24h for 22 days plus ceftriaxone 1 g IV q24h for 2 days, followed by an optional switch to azithromycin 500 mg PO q24h at the investigator's discretion. 
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*Comparator regimen consisted of azithromycin 500 mg IV q24h for r2 days plus ceftriaxone 1 g IV q24h for 2 days, followed by an optional switch to azithromycin 500 mg PO q24h at the investigator's discretion. Table IX, the overall incidence of drugrelated AEs for all body systems was 5.3% in the levofloxacin group and 9.3% in the azithromycin group. The most common drug-related AEs in the azithromycin group were diarrhea (4.2%), vein disorders (2.5%), and pruritus (1.7%), whereas no drug-related AE occurred in ~1 .O% of levofloxacin-treated patients. One patient receiving levofloxacin had a serious drugrelated AE, compared with 7 patients receiving azithromycin. Six deaths occurred during the study: 2 in the levofloxacin group and 4 in the azithromycin group. None of the deaths were considered to be treatment related.
DISCUSSION
Clinical practice guidelines are important tools when choosing treatment for a particular disease state. The IDSA guidelines recommend doxycycline, macrolides, or fluoroquinolones as the preferred antimicrobial agents for the empiric therapy of most outpatient cases of CAP, and either a fluoroquinolone alone or a beta-lactam/ beta-lactamase inhibitor or extendedspectrum cephalosporin combined with a macrolide for most hospitalized patients with CAP in general medical wards.9 In the present trial, levofloxacin monotherapy was at least as effective and well tolerated as traditional combination therapy with a macrolide and a beta-lactam in the treatment of moderate to severe CAP. The pharmacokinetics of levofloxacin are such that the drug achieves high concentrations soon after dosing that are sustained at levels far exceeding the MIC required to achieve 90% inhibition of most respiratory pathogens in both serum and lung tissue." Reports sugg est that levofloxacin is effective in the treatment of pneumococcal CAP (including bacteremic infections)
in patients who have failed macrolide therapy, as well as patients with bacteremic CAP. 18, 19 Most patients in the present study had significant disease, as indicated by a mean Fine risk score of 93.4. They were randomized to once-daily treatment with levofloxacin IV or PO or r2 days of combination therapy with azithromycin and ceftriaxone IV, followed by an optional transition to azithromycin PO, for a total duration of treatment of ~10 days. The addition of ceftriaxone to the initial azithromycin regimen was considered a necessary safeguard in patients with pneumococcal bacteremia. However, because azithromycin was not used as monotherapy, this made it difficult to evaluate the clinical and microbiologic outcome with azithromycin alone.
The results of this trial suggest that levofloxacin is at least as effective as azithromycin, despite the fact that azithromycin was initially coadministered with ceftriaxone.
Some of the inclusion and exclusion criteria may have limited the ability to extrapolate from the results. The clinical success rate in clinically evaluable patients was 94.1% in the levofloxacin group and 92.3% in the azithromycin group. The respective microbiologic eradication rates were 89.5% and 92.3%. A strong correlation was observed between the clinical and microbiologic response in both treatment groups. Twelve patients in the levofloxacin group received oral levofloxacin only, and the clinical success rate in this group was 100%. A total of 5 patients were classified as treatment failures, all of whom had received study drug for s5 days and all with significant comorbidity.
Levofloxacin was as well tolerated as azithromycin, with an overall incidence of AEs related to all body systems of 5.3% and 9.3% of patients, respectively. The most common drug-related AEs associated with azithromycin therapy were diarrhea, vein disorders, and pruritus, whereas no drug-related AE occurred in >I .O% of levofloxacin-treated patients. Although 6 deaths occurred during the study, none were considered treatment related.
CONCLUSIONS
Based on its clinical and microbiologic efficacy, as well as its favorable tolerability profile, levofloxacin monotherapy appears to be effective in the management of hospitalized patients with moderate to severe CAP.
